

3-14-18

→ oppose

HB5223: A Perilous Prescription

- Imposes **intrusive reporting requirements** on prescription drug manufacturers selling high-cost drug treatments
- **Forces manufacturers to disclose confidential business information** about research and development costs
- Research shows that **drug costs** as a percentage of healthcare expenses **have remained relatively constant** over the years.
- Prescription drugs account for approximately 10 percent of all medical expenditures and 20 percent of serious diseases, such as cancer.
- The Congressional Budget Office (CBO) estimated that for every one percent increase in medication utilization, overall Medicare program costs fell by one-fifth of a percent.
- Since 1991, the cancer death rate has dropped by 25 percent thanks to enormous advances in disease treatment.

Passing HB5223 will likely leave patients with fewer treatment options, leaving those without the financial resources to go out-of-state with disproportionately less treatments available to them.